Trial Information

Summary: A Double-Blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam (ucb34714) in Subjects (= 16 to 75 Years Old) With Partial Onset Seizures

An International, Double-Blind, Randomized, Multi-Center, Parallel Group, Historical-Control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (= 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.

Inclusion Criteria:

• Subjects from 16 to 75 years, both inclusive
• Well-characterized focal epilepsy or epileptic syndrome.
• Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not secondarily generalized per 4 weeks during the 8-week Baseline Period.
• Subjects on a stable dose of at least 1 but no more than 2 concomitant AEDs with the second AED ? 50% of the minimum recommended maintenance dose.

Exclusion Criteria:

• Seizure type IA non-motor as only seizure type.
• History or presence of seizures occurring too frequently or indistinctly separated to be reliably counted during the 6 months preceding Visit 1 or during Baseline.
• Other serious uncontrolled disease.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: August 15, 2008 at 1:29:49 PM